Foluso O Ademuyiwa1, Yu Tao2, Jingqin Luo2, Katherine Weilbaecher3, Cynthia X Ma3. 1. Division of Oncology, Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA. bisiademuyiwa@wustl.edu. 2. Division of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA. 3. Division of Oncology, Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA.
Abstract
BACKGROUND: Triple-negative breast cancer (TNBC) occurs at higher frequency in African Americans compared with Caucasians. It is unclear if the biology of TNBC is different in African American versus Caucasians. In this study, we sought to evaluate racial differences in the molecular pathology of TNBC. METHODS: Using data from The Cancer Genome Atlas, we identified TNBC patients with information on race. We analyzed differences in clinical characteristics, tumor somatic mutations, and gene expression patterns by race from whole exome and microarray data. RESULTS: 1104 patients were identified, of which 178 had TNBC. TNBC was more frequent in African Americans than Caucasians (33.3 vs 14.9%). Although more African Americans than Caucasians overall were classified as basal-like from PAM50 gene expression (34.8 vs 16.1%), no differences in the TNBC cohort were observed. Median tumor somatic mutation counts were higher in African Americans versus Caucasians (39.5 vs 34), but no racial differences in the mutation counts in TNBC were observed. Somatic mutation analysis revealed racial differences in specific high prevalence genes in all patients (TP53 46% in African Americans vs 27% in Caucasians; PIK3CA 23% in African Americans vs 34% in Caucasians; and MLL3 12% in African Americans vs 6% in Caucasians). TNBC patients did not have any specific high prevalence genes associated with racial differences. There were no racial differences in gene expression patterns in selected genes involved in breast cancer biology. Overall, African Americans had shorter TTP and worse DFS. Racial differences in clinical outcomes were not observed in TNBC. CONCLUSION: The mutational landscape of TNBC is similar between African Americans and Caucasians. The higher frequency of TNBC in African Americans is therefore not associated with a different genomic profile of commonly established tumor regulatory pathway genes. Other modifiable factors may exist that contribute to the racial disparity in TNBC.
BACKGROUND: Triple-negative breast cancer (TNBC) occurs at higher frequency in African Americans compared with Caucasians. It is unclear if the biology of TNBC is different in African American versus Caucasians. In this study, we sought to evaluate racial differences in the molecular pathology of TNBC. METHODS: Using data from The Cancer Genome Atlas, we identified TNBC patients with information on race. We analyzed differences in clinical characteristics, tumor somatic mutations, and gene expression patterns by race from whole exome and microarray data. RESULTS: 1104 patients were identified, of which 178 had TNBC. TNBC was more frequent in African Americans than Caucasians (33.3 vs 14.9%). Although more African Americans than Caucasians overall were classified as basal-like from PAM50 gene expression (34.8 vs 16.1%), no differences in the TNBC cohort were observed. Median tumor somatic mutation counts were higher in African Americans versus Caucasians (39.5 vs 34), but no racial differences in the mutation counts in TNBC were observed. Somatic mutation analysis revealed racial differences in specific high prevalence genes in all patients (TP53 46% in African Americans vs 27% in Caucasians; PIK3CA 23% in African Americans vs 34% in Caucasians; and MLL3 12% in African Americans vs 6% in Caucasians). TNBC patients did not have any specific high prevalence genes associated with racial differences. There were no racial differences in gene expression patterns in selected genes involved in breast cancer biology. Overall, African Americans had shorter TTP and worse DFS. Racial differences in clinical outcomes were not observed in TNBC. CONCLUSION: The mutational landscape of TNBC is similar between African Americans and Caucasians. The higher frequency of TNBC in African Americans is therefore not associated with a different genomic profile of commonly established tumor regulatory pathway genes. Other modifiable factors may exist that contribute to the racial disparity in TNBC.
Entities:
Keywords:
Genomics; Survival; Triple negative breast cancer
Authors: E J Duell; R C Millikan; G S Pittman; S Winkel; R M Lunn; C K Tse; A Eaton; H W Mohrenweiser; B Newman; D A Bell Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-03 Impact factor: 4.254
Authors: Lori A Field; Brad Love; Brenda Deyarmin; Jeffrey A Hooke; Craig D Shriver; Rachel E Ellsworth Journal: Cancer Date: 2011-07-28 Impact factor: 6.860
Authors: Erica T Warner; Rulla M Tamimi; Melissa E Hughes; Rebecca A Ottesen; Yu-Ning Wong; Stephen B Edge; Richard L Theriault; Douglas W Blayney; Joyce C Niland; Eric P Winer; Jane C Weeks; Ann H Partridge Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Michelle Shayne; Jeffrey Crawford; David C Dale; Eva Culakova; Gary H Lyman Journal: Breast Cancer Res Treat Date: 2006-05-17 Impact factor: 4.872
Authors: Joseph A Sparano; Molin Wang; Fengmin Zhao; Vered Stearns; Silvana Martino; Jennifer A Ligibel; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson Journal: J Natl Cancer Inst Date: 2012-01-16 Impact factor: 13.506
Authors: Ying Liu; Deirdre K Tobias; Kathleen M Sturgeon; Bernard Rosner; Vasanti Malik; Elizabeth Cespedes; Amit D Joshi; A Heather Eliassen; Graham A Colditz Journal: Int J Cancer Date: 2016-05-17 Impact factor: 7.396
Authors: Huiyan Ma; Yani Lu; Kathleen E Malone; Polly A Marchbanks; Dennis M Deapen; Robert Spirtas; Ronald T Burkman; Brian L Strom; Jill A McDonald; Suzanne G Folger; Michael S Simon; Jane Sullivan-Halley; Michael F Press; Leslie Bernstein Journal: BMC Cancer Date: 2013-05-04 Impact factor: 4.430
Authors: Eric Hahnen; Jan Hauke; Christoph Engel; Guido Neidhardt; Kerstin Rhiem; Rita K Schmutzler Journal: Breast Care (Basel) Date: 2017-02-24 Impact factor: 2.860
Authors: S David Nathanson; David Krag; Henry M Kuerer; Lisa A Newman; Markus Brown; Dontscho Kerjaschki; Ethel R Pereira; Timothy P Padera Journal: Clin Exp Metastasis Date: 2018-05-23 Impact factor: 5.150
Authors: Angela R Omilian; Lei Wei; Chi-Chen Hong; Elisa V Bandera; Song Liu; Thaer Khoury; Christine B Ambrosone; Song Yao Journal: Breast Cancer Res Treat Date: 2020-05-21 Impact factor: 4.872
Authors: Rafael Guerrero-Preston; Fahcina Lawson; Sebastian Rodriguez-Torres; Maartje G Noordhuis; Francesca Pirini; Laura Manuel; Blanca L Valle; Tal Hadar; Bianca Rivera; Oluwasina Folawiyo; Adriana Baez; Luigi Marchionni; Wayne M Koch; William H Westra; Young J Kim; James R Eshleman; David Sidransky Journal: Cancer Prev Res (Phila) Date: 2019-02-18
Authors: Olivia D Lara; Ying Wang; Amma Asare; Tao Xu; Hua-Sheng Chiu; Yuexin Liu; Wei Hu; Pavel Sumazin; Shitanshu Uppal; Lin Zhang; J Alejandro Rauh-Hain; Anil K Sood Journal: Cancer Date: 2019-11-15 Impact factor: 6.860
Authors: Jiao Yuan; Zhongyi Hu; Brandon A Mahal; Sihai D Zhao; Kevin H Kensler; Jingjiang Pi; Xiaowen Hu; Youyou Zhang; Yueying Wang; Junjie Jiang; Chunsheng Li; Xiaomin Zhong; Kathleen T Montone; Guoqiang Guan; Janos L Tanyi; Yi Fan; Xiaowei Xu; Mark A Morgan; Meixiao Long; Yuzhen Zhang; Rugang Zhang; Anil K Sood; Timothy R Rebbeck; Chi V Dang; Lin Zhang Journal: Cancer Cell Date: 2018-10-08 Impact factor: 31.743
Authors: Brittany D Jenkins; Rachel N Martini; Rupali Hire; Andrea Brown; Briana Bennett; I'nasia Brown; Elizabeth W Howerth; Mary Egan; Jamie Hodgson; Clayton Yates; Rick Kittles; Dhananjay Chitale; Haythem Ali; David Nathanson; Petros Nikolinakos; Lisa Newman; Michele Monteil; Melissa B Davis Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-04 Impact factor: 4.090